Omeros (NASDAQ:OMER) Upgraded at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.

OMER has been the topic of several other research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Tuesday. D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

Shares of NASDAQ OMER opened at $7.36 on Tuesday. The firm has a fifty day moving average of $8.58 and a 200 day moving average of $7.61. The firm has a market cap of $426.51 million, a PE ratio of -3.19 and a beta of 2.03. Omeros has a one year low of $2.97 and a one year high of $13.60.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently made changes to their positions in OMER. Truvestments Capital LLC increased its position in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Omeros during the fourth quarter worth $46,000. BNP Paribas Financial Markets increased its holdings in Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares during the last quarter. Finally, Picton Mahoney Asset Management raised its stake in Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 4,404 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.